Dyne Therapeutics, Inc. 4

Jason P. Rhodes, an insider of Dyne Therapeutics, Inc., indirectly sold a total of 2,587,928 shares of common stock through affiliated Atlas Venture funds on August 13–14, 2026, for roughly $65–68 million under a Rule 10b5‑1 trading plan.

On August 13 and 14, 2026, Jason P. Rhodes, a director-level insider associated with Atlas Venture funds, reported a series of Rule 10b5‑1 plan sales of Dyne Therapeutics, Inc. common stock across several affiliated investment vehicles. On August 13, 2026, entities attributed to him sold 268,354, 94,415, and 63,643 shares, respectively, at a weighted average price of approximately $26.20 per share, and on August 14, 2026, they sold 1,359,674, 478,377, and 322,465 shares, respectively, at a weighted average price of approximately $25.00 per share, with sale prices actually ranging from about $25.8788 to $26.48 on August 13 and from $25.00 to $25.8916 on August 14. In total, 2,587,928 shares were disposed of for an estimated aggregate value of roughly $65–68 million based on the reported average prices. After these transactions, the reporting person’s indirect ownership through various Atlas Venture entities stands at 3,801,128 shares, 1,045,735 shares, 751,411 shares, 2,441,454 shares, 567,358 shares, 428,946 shares, plus 2,962 shares held through another indirect vehicle, though he disclaims beneficial ownership beyond his pecuniary interest in each fund. The sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on July 13, 2026, and the prices disclosed are weighted averages across multiple trades within the stated ranges.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

fda

Accession

0001577014-26-000016

Alert Tier

7